| 255.36 Delayed Data As of 11:13am ET |  +2.95 / +1.17%Today’s Change | 214.46 Today|||52-Week Range 262.56 | +2.02% Year-to-Date |
| Roche to Create Companion Diagnostic Test for Merck's Keytruda 9:30am / Zacks.com - Paid Partner Content | AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study Dec 06 / Zacks.com - Paid Partner Content |
| Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO Dec 11 / Zacks.com - Paid Partner Content | Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx Dec 06 / Zacks.com - Paid Partner Content |
| Roche's Tecentriq Gets FDA Approval for First-Line NSCLC Dec 10 / Zacks.com - Paid Partner Content | J&J's Blood Cancer Drugs Succeed in Label Expansion Studies Dec 05 / Zacks.com - Paid Partner Content |
| Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend Dec 10 / Zacks.com - Paid Partner Content | Roche's Tecentriq Combination Gets Priority Review by FDA Dec 05 / Zacks.com - Paid Partner Content |
| Roche's Kadcyla Halves Death Risk in Breast Cancer Study Dec 06 / Zacks.com - Paid Partner Content | Roche Announces Positive Data on Venclexta/Venclyxto at ASH Dec 04 / Zacks.com - Paid Partner Content |
| Previous close | 252.41 |
| Today’s open | 255.36 |
| Day’s range | 255.36 - 255.36 |
| Volume | 16 |
| Average volume (3 months) | 362 |
| Market cap | $39.4B |
| Earnings growth (last year) | -9.88% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +5.48% |
| P/E ratio | 19.7 |
| Price/Sales | 4.01 |
| Price/Book | 7.74 |
| No competitors data available. |
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $54.2B |
| Annual profit (last year) | $8.8B |
| Net profit margin | 16.20% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Severin Schwan |
Chief Financial & Information Technology Officer Alan Hippe |
Corporate headquarters Basel, Basel-stadt (basle Town) |
